English

Allogene Therapeutics, Inc.

EDGAR

ALLO Quarterly report (10-Q) · filed 2026-08-12

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 22K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.64 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 4640000 USD Source

Operating margin

-1,011.21%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -46920000 USD Source
Revenue: 4640000 USD Source

Operating cash flow

-32 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -44909000 USD Source
Operating Cash Flow: -12913000 USD Source

Free cash flow

-32.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -44909000 USD Source
Operating Cash Flow: -12913000 USD Source
Capital Expenditure: 159000 USD Source
Capital Expenditure: 9000 USD Source

Cash and cash equivalents: 38.6 million USD 2026-06-30 Source
Exact value

38626000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 345 million shares 2026-06-30 Source
Exact value

345345427 shares

Reported share-count change

56.88% · 125 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

220133876 shares · 2025-06-30· Source
345345427 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-165 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -41400000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -190886000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -152076000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -42607000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -42677000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-102 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -121647000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -91959000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -149246000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -121647000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12913000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -44909000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12913000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

402 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 386000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 143000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 386000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 386000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 9000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 159000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 9000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-103 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -121647000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -91959000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -149246000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -121647000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12913000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -44909000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12913000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 386000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 143000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 386000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 386000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 9000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 159000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 9000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 22,000

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 22000 = -22000 USD

22000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Year-over-year change in Revenue: -22000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1230981 Filing: 000162828026017242 Input fundies:Revenue: 22000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1231783 Filing: 000162828026017242
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 66.7 million

Prior period

−USD 257.59 million

2024-01-01 – 2024-12-31
Current period

−USD 190.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-190886000 − -257590000 = 66704000 USD

-257590000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-190886000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Year-over-year change in Net income: 66704000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -190886000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1959037 Filing: 000162828026017242 Input fundies:NetIncome: -257590000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1959712 Filing: 000162828026017242
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 51.05 million

Prior period

−USD 200.3 million

2024-01-01 – 2024-12-31
Current period

−USD 149.25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-149246000 − -200300000 = 51054000 USD

-200300000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-149246000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Year-over-year change in Operating cash flow: 51054000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -149246000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1352668 Filing: 000162828026017242 Input fundies:OperatingCashFlow: -200300000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1353321 Filing: 000162828026017242
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-44.4%

Prior period

USD 694,000

2024-01-01 – 2024-12-31
Current period

USD 386,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

386000 − 694000 = -308000 USD

694000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
386000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Year-over-year change in Capital expenditure: -308000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 386000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1354678 Filing: 000162828026017242 Input fundies:CapitalExpenditure: 694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1355237 Filing: 000162828026017242
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 209.32 million
Operating income −USD 209.32 million
Tax, interest and other Derived −USD 18.43 million
Net income −USD 190.89 million

Cash

Operating cash flow −USD 149.25 million
Capital expenditure USD 386,000
Free cash flow Derived −USD 149.63 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 258% of revenue.
2022 Operating loss: operating costs were 215,187% of revenue.
2023 Operating loss: operating costs were 345,086% of revenue.
2024 Operating loss: operating costs were 1,241,914% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	0	202008000 Derived	-202008000	-17414000 Derived	-184594000	-188141000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -202008000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -184594000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -137350000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 50791000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	258243000 Derived	-258243000	58138000 Derived	-316381000	-181051000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -258243000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -316381000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -115093000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 65958000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	114089000	294281000 Derived	-180192000	1859000 Derived	-182051000	-206258000 Derived	Source 2021-01-01 – 2021-12-31: 114089000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -180192000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -182051000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -184812000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 21446000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	156000	335692000 Derived	-335536000	4878000 Derived	-340414000	-225710000 Derived	Source 2022-01-01 – 2022-12-31: 156000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -335536000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -340414000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -220519000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 5191000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	95000	327832000 Derived	-327737000	-472000 Derived	-327265000	-239249000 Derived	Source 2023-01-01 – 2023-12-31: 95000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -327737000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -327265000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -237733000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1516000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	22000	273221000 Derived	-273199000	-15609000 Derived	-257590000	-200994000 Derived	Source 2024-01-01 – 2024-12-31: 22000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -273199000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -257590000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -200300000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 694000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	209315000 Derived	-209315000	-18429000 Derived	-190886000	-149632000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -209315000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -190886000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -149246000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 386000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	114089000	Revenue: 114089000 Open source
20222022-12-31	Revenue	156000	Revenue: 156000 Open source
20232023-12-31	Revenue	95000	Revenue: 95000 Open source
20242024-12-31	Revenue	22000	Revenue: 22000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 114089000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	-99.9%	Revenue: 156000 Open source Revenue: 114089000 Open source
20232023-12-31	Year over year	-39.1%	Revenue: 95000 Open source Revenue: 156000 Open source
20242024-12-31	Year over year	-76.8%	Revenue: 22000 Open source Revenue: 95000 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 22000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,241,813.6% 2024

Net margin -1,170,863.6% 2024

Free cash flow margin -913,609.1% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	Not reported	Operating Income: -202008000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -258243000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-157.9%	Operating Income: -180192000 Open source Revenue: 114089000 Open source
20222022-12-31	Operating margin	-215,087.2%	Operating Income: -335536000 Open source Revenue: 156000 Open source
20232023-12-31	Operating margin	-344,986.3%	Operating Income: -327737000 Open source Revenue: 95000 Open source
20242024-12-31	Operating margin	-1,241,813.6%	Operating Income: -273199000 Open source Revenue: 22000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -209315000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -184594000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -316381000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-159.6%	Net Income: -182051000 Open source Revenue: 114089000 Open source
20222022-12-31	Net margin	-218,214.1%	Net Income: -340414000 Open source Revenue: 156000 Open source
20232023-12-31	Net margin	-344,489.5%	Net Income: -327265000 Open source Revenue: 95000 Open source
20242024-12-31	Net margin	-1,170,863.6%	Net Income: -257590000 Open source Revenue: 22000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -190886000 Open source Revenue: 0 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -137350000 Open source Capital Expenditure: 50791000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -115093000 Open source Capital Expenditure: 65958000 Open source
20212021-12-31	Free cash flow margin	-180.8%	Revenue: 114089000 Open source Operating Cash Flow: -184812000 Open source Capital Expenditure: 21446000 Open source
20222022-12-31	Free cash flow margin	-144,685.9%	Revenue: 156000 Open source Operating Cash Flow: -220519000 Open source Capital Expenditure: 5191000 Open source
20232023-12-31	Free cash flow margin	-251,841.1%	Revenue: 95000 Open source Operating Cash Flow: -237733000 Open source Capital Expenditure: 1516000 Open source
20242024-12-31	Free cash flow margin	-913,609.1%	Revenue: 22000 Open source Operating Cash Flow: -200300000 Open source Capital Expenditure: 694000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -149246000 Open source Capital Expenditure: 386000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -149.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-137350000	Operating Cash Flow: -137350000 Open source
20202020-12-31	Operating cash flow	-115093000	Operating Cash Flow: -115093000 Open source
20212021-12-31	Operating cash flow	-184812000	Operating Cash Flow: -184812000 Open source
20222022-12-31	Operating cash flow	-220519000	Operating Cash Flow: -220519000 Open source
20232023-12-31	Operating cash flow	-237733000	Operating Cash Flow: -237733000 Open source
20242024-12-31	Operating cash flow	-200300000	Operating Cash Flow: -200300000 Open source
20252025-12-31	Operating cash flow	-149246000	Operating Cash Flow: -149246000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -149.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-188141000	Operating Cash Flow: -137350000 Open source Capital Expenditure: 50791000 Open source
20202020-12-31	Free cash flow	-181051000	Operating Cash Flow: -115093000 Open source Capital Expenditure: 65958000 Open source
20212021-12-31	Free cash flow	-206258000	Operating Cash Flow: -184812000 Open source Capital Expenditure: 21446000 Open source
20222022-12-31	Free cash flow	-225710000	Operating Cash Flow: -220519000 Open source Capital Expenditure: 5191000 Open source
20232023-12-31	Free cash flow	-239249000	Operating Cash Flow: -237733000 Open source Capital Expenditure: 1516000 Open source
20242024-12-31	Free cash flow	-200994000	Operating Cash Flow: -200300000 Open source Capital Expenditure: 694000 Open source
20252025-12-31	Free cash flow	-149632000	Operating Cash Flow: -149246000 Open source Capital Expenditure: 386000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

29.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	12.4%	Total Liabilities: 88779000 Open source Total Assets: 717802000 Open source
20202020-12-31	Liabilities / assets	12.1%	Total Liabilities: 148212000 Open source Total Assets: 1227829000 Open source
20212021-12-31	Liabilities / assets	12%	Total Liabilities: 125628000 Open source Total Assets: 1050828000 Open source
20222022-12-31	Liabilities / assets	18.8%	Total Liabilities: 154697000 Open source Total Assets: 821579000 Open source
20232023-12-31	Liabilities / assets	20.3%	Total Liabilities: 130604000 Open source Total Assets: 642837000 Open source
20242024-12-31	Liabilities / assets	23.1%	Total Liabilities: 126531000 Open source Total Assets: 548710000 Open source
20252025-12-31	Liabilities / assets	29.7%	Total Liabilities: 123363000 Open source Total Assets: 415905000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.93× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	16.46×	Current Assets: 544576000 Open source Current Liabilities: 33079000 Open source
20202020-12-31	Current assets / current liabilities	8.96×	Current Assets: 845130000 Open source Current Liabilities: 94320000 Open source
20212021-12-31	Current assets / current liabilities	9.84×	Current Assets: 471323000 Open source Current Liabilities: 47907000 Open source
20222022-12-31	Current assets / current liabilities	9.84×	Current Assets: 528824000 Open source Current Liabilities: 53728000 Open source
20232023-12-31	Current assets / current liabilities	12.38×	Current Assets: 459115000 Open source Current Liabilities: 37079000 Open source
20242024-12-31	Current assets / current liabilities	8.54×	Current Assets: 303386000 Open source Current Liabilities: 35523000 Open source
20252025-12-31	Current assets / current liabilities	7.93×	Current Assets: 257749000 Open source Current Liabilities: 32514000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 211.51 million Exact value Exact value: -211505000 USD 2018-01-01 – 2018-12-31: -211505000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2018-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -211505000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -211505000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000009/allo-20201231.htm#2520202 Filing: 000173728721000009 The citation records this snapshot. The page link may show a newer release later.	−USD 44.65 million Exact value Exact value: -44653000 USD 2018-01-01 – 2018-12-31: -44653000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2018-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -44653000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44653000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000009/allo-20201231.htm#1588219 Filing: 000173728721000009 The citation records this snapshot. The page link may show a newer release later.	USD 3.23 million Exact value Exact value: 3234000 USD 2018-01-01 – 2018-12-31: 3234000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2018-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 3234000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3234000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000009/allo-20201231.htm#1592030 Filing: 000173728721000009 The citation records this snapshot. The page link may show a newer release later.	−USD 47.89 million Calculation and evidence -44653000 − 3234000 USD Exact free cash flow: -47887000 USD 2018-01-01 – 2018-12-31: -44653000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3234000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2018-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -47887000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44653000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000009/allo-20201231.htm#1588219 Filing: 000173728721000009 Input fundies:CapitalExpenditure: 3234000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000009/allo-20201231.htm#1592030 Filing: 000173728721000009 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 184.59 million Exact value Exact value: -184594000 USD 2019-01-01 – 2019-12-31: -184594000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2019-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -184594000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -184594000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm#2351953 Filing: 000173728722000013 The citation records this snapshot. The page link may show a newer release later.	−USD 137.35 million Exact value Exact value: -137350000 USD 2019-01-01 – 2019-12-31: -137350000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2019-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -137350000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -137350000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm#1491529 Filing: 000173728722000013 The citation records this snapshot. The page link may show a newer release later.	USD 50.79 million Exact value Exact value: 50791000 USD 2019-01-01 – 2019-12-31: 50791000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2019-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 50791000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 50791000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm#1495344 Filing: 000173728722000013 The citation records this snapshot. The page link may show a newer release later.	−USD 188.14 million Calculation and evidence -137350000 − 50791000 USD Exact free cash flow: -188141000 USD 2019-01-01 – 2019-12-31: -137350000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 50791000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2019-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -188141000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -137350000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm#1491529 Filing: 000173728722000013 Input fundies:CapitalExpenditure: 50791000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm#1495344 Filing: 000173728722000013 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 316.38 million Exact value Exact value: -316381000 USD 2020-01-01 – 2020-12-31: -316381000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2020-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -316381000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -316381000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#2169248 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 115.09 million Exact value Exact value: -115093000 USD 2020-01-01 – 2020-12-31: -115093000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2020-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -115093000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -115093000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1630767 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	USD 65.96 million Exact value Exact value: 65958000 USD 2020-01-01 – 2020-12-31: 65958000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2020-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 65958000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 65958000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1372004 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 181.05 million Calculation and evidence -115093000 − 65958000 USD Exact free cash flow: -181051000 USD 2020-01-01 – 2020-12-31: -115093000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 65958000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2020-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -181051000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -115093000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1630767 Filing: 000173728724000018 Input fundies:CapitalExpenditure: 65958000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1372004 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 182.05 million Exact value Exact value: -182051000 USD 2021-01-01 – 2021-12-31: -182051000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2021-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -182051000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -182051000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#2168563 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 184.81 million Exact value Exact value: -184812000 USD 2021-01-01 – 2021-12-31: -184812000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2021-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -184812000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -184812000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1628960 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	USD 21.45 million Exact value Exact value: 21446000 USD 2021-01-01 – 2021-12-31: 21446000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2021-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 21446000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21446000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1371409 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 206.26 million Calculation and evidence -184812000 − 21446000 USD Exact free cash flow: -206258000 USD 2021-01-01 – 2021-12-31: -184812000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 21446000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2021-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -206258000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -184812000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1628960 Filing: 000173728724000018 Input fundies:CapitalExpenditure: 21446000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1371409 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 340.41 million Exact value Exact value: -340414000 USD 2022-01-01 – 2022-12-31: -340414000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2022-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -340414000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -340414000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#2167878 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 220.52 million Exact value Exact value: -220519000 USD 2022-01-01 – 2022-12-31: -220519000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2022-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -220519000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -220519000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1627153 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	USD 5.19 million Exact value Exact value: 5191000 USD 2022-01-01 – 2022-12-31: 5191000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2022-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 5191000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5191000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1370815 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.	−USD 225.71 million Calculation and evidence -220519000 − 5191000 USD Exact free cash flow: -225710000 USD 2022-01-01 – 2022-12-31: -220519000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 5191000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2022-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -225710000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -220519000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1627153 Filing: 000173728724000018 Input fundies:CapitalExpenditure: 5191000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000018/allo-20221231.htm#1370815 Filing: 000173728724000018 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 327.27 million Exact value Exact value: -327265000 USD 2023-01-01 – 2023-12-31: -327265000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2023-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -327265000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -327265000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm#1959144 Filing: 000173728725000036 The citation records this snapshot. The page link may show a newer release later.	−USD 237.73 million Exact value Exact value: -237733000 USD 2023-01-01 – 2023-12-31: -237733000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2023-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -237733000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -237733000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm#1369135 Filing: 000173728725000036 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1516000 USD 2023-01-01 – 2023-12-31: 1516000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2023-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 1516000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1516000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm#1371067 Filing: 000173728725000036 The citation records this snapshot. The page link may show a newer release later.	−USD 239.25 million Calculation and evidence -237733000 − 1516000 USD Exact free cash flow: -239249000 USD 2023-01-01 – 2023-12-31: -237733000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1516000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2023-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -239249000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -237733000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm#1369135 Filing: 000173728725000036 Input fundies:CapitalExpenditure: 1516000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm#1371067 Filing: 000173728725000036 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 257.59 million Exact value Exact value: -257590000 USD 2024-01-01 – 2024-12-31: -257590000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2024-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -257590000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -257590000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1959712 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	−USD 200.3 million Exact value Exact value: -200300000 USD 2024-01-01 – 2024-12-31: -200300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2024-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -200300000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -200300000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1353321 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	USD 694,000 Exact value Exact value: 694000 USD 2024-01-01 – 2024-12-31: 694000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2024-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 694000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1355237 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	−USD 200.99 million Calculation and evidence -200300000 − 694000 USD Exact free cash flow: -200994000 USD 2024-01-01 – 2024-12-31: -200300000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 694000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2024-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -200994000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -200300000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1353321 Filing: 000162828026017242 Input fundies:CapitalExpenditure: 694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1355237 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 190.89 million Exact value Exact value: -190886000 USD 2025-01-01 – 2025-12-31: -190886000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Net Income: -190886000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -190886000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1959037 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	−USD 149.25 million Exact value Exact value: -149246000 USD 2025-01-01 – 2025-12-31: -149246000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Operating Cash Flow: -149246000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -149246000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1352668 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	USD 386,000 Exact value Exact value: 386000 USD 2025-01-01 – 2025-12-31: 386000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Capital Expenditure: 386000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 386000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1354678 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.	−USD 149.63 million Calculation and evidence -149246000 − 386000 USD Exact free cash flow: -149632000 USD 2025-01-01 – 2025-12-31: -149246000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 386000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Allogene Therapeutics, Inc. · 2025-12-31 Allogene Therapeutics, Inc. (edgar:1737287) Free cash flow: -149632000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:21:02Z Snapshot: d07109c063bef6bca39c03c77cd900eb3e752b77b6b3f1c34f26ec12650daf11 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737287?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -149246000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1352668 Filing: 000162828026017242 Input fundies:CapitalExpenditure: 386000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm#1354678 Filing: 000162828026017242 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

37 filings · 2,112 latest values · 2,112 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001737287, 1737287, ALLO, edgar:1737287

Also known as Allogene Therapeutics, Inc., Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation